PET imaging is one of the most powerful and least invasive ways of observing the metabolic activity of an organ and a tumor or any cells in body tissue. Today, the radiopharmaceutical molecule widely used in PET imaging is 18F-FDG (FluoroDeoxyGlucose), which is produced in large-size cyclotrons and distributed by major private centers. Financial and technical constraints limit the use of more than 200 other molecules that could be of clinical interest. Medical and research centers are unable to use more specific molecules, with an often short half-life. This limited access has direct consequences on patient care: less specific radiopharmaceuticals, less adequate treatment.
Contact PMBby e-mail
FIGEDIM Project 2020 - Greater East Region
PMB and Nancyclotep join forces to meet the Challenges of tomorrow’s healthcare:
- Promote the research and development of new molecules of clinical interest
- Improve and optimize iMiGiNE's industrial processes and operations in a hospital environment
- Participate in the transition from conventional to personalized medicine, particularly for companion tests related to targeted treatments